[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640027":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":11,"centralContacts":38,"locations":44,"responsibleParty":78,"collaborators":11,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":11,"eligibilityCriteria":85,"healthyVolunteers":82,"sex":86,"minAge":87,"maxAge":11,"enrollmentInfo":88,"targetDuration":11,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":101,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Kupando GmbH","INDUSTRY",[8,14,17,20,23,26,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose level 1","EXPERIMENTAL",null,[13],"Drug: KUP-101A",{"label":15,"type":10,"description":11,"interventionNames":16},"Dose level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Dose level 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Dose level 4",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Dose level 5",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Dose level 6",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"Dose level 7",[13],[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"DRUG","KUP-101A","Intravenous infusion of KUP-101A",[9,15,18,21,24,27,30],[39],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"Clinical Operations","CONTACT","+49 30 52 00 58 60 20","clinicaltrials@kupando.com",[45,59,68],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":11},"Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie","RECRUITING","Munich","Bavaria","80337","Germany","DE",{"type":54,"coordinates":55},"Point",[56,57],11.57549,48.13743,{"lat":57,"lon":56},{"facility":60,"status":47,"city":61,"state":49,"zip":62,"country":51,"countryCode":52,"cosmosGeoPoint":63,"geoPoint":67,"contacts":11},"Universitätsklinikum Würzburg","Würzburg","97080",{"type":54,"coordinates":64},[65,66],9.95121,49.79391,{"lat":66,"lon":65},{"facility":69,"status":47,"city":70,"state":71,"zip":72,"country":51,"countryCode":52,"cosmosGeoPoint":73,"geoPoint":77,"contacts":11},"Fachklinik Hornheide","Münster","North Rhine-Westphalia","48157",{"type":54,"coordinates":74},[75,76],7.62571,51.96236,{"lat":76,"lon":75},{"type":79,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100640027","phase-1-a-first-in-human-study-to-evaluate-the-safety-pharmacokinetics-and-pharmacodynamics-of-kup-101a-in-patients-with-selected-advanced-solid-tumors-100640027",false,"NCT07600476","A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed cancer with evidence of advanced disease for which no other standard treatment is available\n* ECOG Performance status of 0 to 2\n* Adequate hematological, renal, and hepatic organ function\n\nExclusion Criteria:\n\n* Previous systemic treatment with TLR agonists, with the exception of TLR agonists used as vaccine adjuvants.\n* Known additional malignancy that is progressing or requires active treatment\n* Diagnosis of immunodeficiency\n* Active autoimmune disease not caused by prior anticancer treatment that required systemic immunosuppressive treatment in the past 2 years\n* Active autoimmune disease caused by prior anticancer treatment, unless currently controlled by replacement therapy only.\n* Any kind of leukemia\n* Previously received an organ transplant (other than corneal transplants) or hematopoietic stem cell transplantation\n* Known active central nervous system metastases and\u002For carcinomatous meningitis\n* Cerebral vascular event within 6 months before Screening\n* Unstable cardiopulmonary status defined by uncontrolled congestive heart failure of New York Heart Association Grade III or IV, unstable angina, or myocardial infarction within 6 months before Screening\n* High grade ocular disease such as uncontrolled glaucoma","ALL","18 Years",{"count":89,"type":90},21,"ESTIMATED","INTERVENTIONAL",[93],"PHASE1","The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.",[96,97,98,99,100],"Cutaneous Melanoma","Mucosal Melanoma","Cutaneous Squamous Cell Carcinoma (CSCC)","Merkel Cell Carcinoma of Skin","Basal Cell Carcinoma of Skin",[102,103,104,105,106,107],"TLR4 agonist","TLR7 agonist","TLR4\u002F7 agonist","skin cancer","innate immunity","immunotherapy","2026-08-10",{"date":110,"type":111},"2026-08-12","ACTUAL",{"date":113,"type":111},"2026-07-03",{"date":115,"type":90},"2028-12",{"name":5,"class":6},3]